Comparative Pharmacology
Head-to-head clinical analysis: CELESTONE versus HYDROCORTISONE IN ABSORBASE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CELESTONE versus HYDROCORTISONE IN ABSORBASE.
CELESTONE vs HYDROCORTISONE IN ABSORBASE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Celestone (betamethasone) is a corticosteroid that binds to the glucocorticoid receptor, modulating gene expression to produce anti-inflammatory, immunosuppressive, and antiproliferative effects. It inhibits phospholipase A2, reducing prostaglandin and leukotriene synthesis, and suppresses cytokine production.
Glucocorticoid receptor agonist that modulates gene expression, leading to anti-inflammatory, immunosuppressive, and vasoconstrictive effects.
Betamethasone (Celestone) 0.6-7.2 mg/day orally in divided doses; 0.6-9.0 mg/day IM or IV as betamethasone sodium phosphate; dose adjusted based on severity.
Topical: Apply a thin layer to affected area 2-4 times daily.
None Documented
None Documented
Terminal elimination half-life of betamethasone (active component) is 36-54 hours (mean ~44 hours) in adults, providing sustained adrenal suppression.
Terminal elimination half-life: 1-2 hours (plasma cortisol); biological half-life (duration of action) 8-12 hours due to intracellular receptor effects.
Renal: 75-90% as metabolites (glucuronides and sulfates) and <5% unchanged; biliary/fecal: 10-25%.
Renal: primarily as 17-hydroxycorticosteroids and 17-ketosteroids; <5% unchanged. Biliary/fecal: minimal. Metabolites conjugated with glucuronide or sulfate.
Category C
Category D/X
Corticosteroid
Corticosteroid